Indeed, FSHD patients are characterized by a stable DUX4-fl mRNA expression in a low proportion of muscle cells driving a cascade of toxic signaling pathways resulting in muscle disease [41,60,61,62]. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.